| CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors (NCT02757391) | M.D. Anderson Cancer Center | 2019-08-09 |
| Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (NCT03337087) | Academic and Community Cancer Research United | 2018-11-02 |
| Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer (NCT03257761) | University of Southern California | 2018-02-07 |
| Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations (NCT03040986) | National Cancer Institute (NCI) | 2017-07-21 |
| Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer (NCT02907099) | M.D. Anderson Cancer Center | 2016-12-01 |
| Olaparib in Treating Patients With Stage IV Pancreatic Cancer (NCT02677038) | M.D. Anderson Cancer Center | 2016-11-11 |
| FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (NCT02890355) | National Cancer Institute (NCI) | 2016-10-27 |
| Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer (NCT03073785) | University of Nebraska | 2016-09-16 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (NCT02498613) | National Cancer Institute (NCI) | 2016-08-31 |
| Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (NCT02600949) | M.D. Anderson Cancer Center | 2016-05-11 |
| Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy (NCT02381561) | National Cancer Institute (NCI) | 2016-02-01 |
| Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery (NCT02336087) | City of Hope Medical Center | 2016-01-14 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT02194829) | National Cancer Institute (NCI) | 2014-08-19 |
| Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery (NCT01783171) | National Cancer Institute (NCI) | 2013-01-15 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT01660971) | National Cancer Institute (NCI) | 2012-07-30 |
| Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (NCT00669734) | National Cancer Institute (NCI) | 2010-02-01 |
| Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer (NCT01064622) | National Cancer Institute (NCI) | 2009-09-03 |
| GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (NCT00878163) | National Cancer Institute (NCI) | 2009-03-31 |